Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v3-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2019-11-22 | 2019-11-22 |
| Drug Identification Number | 02329743 | 02329743 |
| Brand name | DRAXIMAGE SODIUM IODIDE I131 CAPSULES, USP THERAPEUTIC | DRAXIMAGE SODIUM IODIDE I131 CAPSULES, USP THERAPEUTIC |
| Common or Proper name | Sodium Iodide 131 | Sodium Iodide 131 |
| Company Name | JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA | JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA |
| Ingredients | SODIUM IODIDE 131 I | SODIUM IODIDE 131 I |
| Strength(s) | 7400MBq | 7400MBq |
| Dosage form(s) | CAPSULE | CAPSULE |
| Route of administration | ORAL | ORAL |
| Packaging size | 1 Capsule/Vial | 1 Capsule/Vial |
| ATC code | V10XA | V10XA |
| ATC description | ||
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | ||
| Actual start date | 2019-11-18 | 2019-11-18 |
| Estimated end date | 2019-12-16 | 2019-12-16 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Awaiting release of a component. DRAXIMAGE® Sodium Iodide I 131 Solution, USP Therapeutic, DIN# 02329778 is currently available and can be used as an alternative during shortage period. | Awaiting release of a component. DRAXIMAGE® Sodium Iodide I 131 Solution, USP Therapeutic, DIN# 02329778 is currently available and can be used as an alternative during shortage period. |
| Health Canada comments |